



Tuesday, 2 June 2009

Manager Companies
Companies Announcement Office
Australian Stock Exchange
Level 4, Stock Exchange Building
20 Bridge Street
Sydney NSW 2000

Dear Sir

**Results of the Extraordinary General Meeting
held on 2 June 2009**

All motions were approved by a show of hands at the meeting.

NuSep Ltd (ASX: NSP) advises the result of each resolution as set out in the proxy summary below:

Resolution	In Favour	Against
1. Return of Capital on or around 11 June 2009	461,512	5,588
2. Grant of listed Options	426,858	20,205
3. Election of Mr. Wilson Wong as a Director	460,450	6,650
4. Grant of Options to Mr. Wilson Wong	450,070	15,950

Please Note

As part of the change of name from NuSep to NxGen the ASX code for NuSep will change to NXG.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative iGels, with a 2 year shelf life.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The first instrument released in 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument separates sperm for fertility treatments such as IVF and is presently undergoing clinical trials.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

Contact:

Prakash Patel

Chief Financial Officer & Company Secretary

+61 2 8977 9000

prakash.patel@nusep.com

About NxGen

NxGen Pharmaceuticals Pty Ltd is a vibrant expanding Pharmaceutical Formulation and Analytical company with a wholesaling and marketing arm.

NxGen's main product developments are:

Sexual Health Products

NxGen has developed a range of products that address erectile dysfunction, premature ejaculation and female sexual dysfunction.

Erectile Dysfunction (ED)

The NxGen developed ED nasal spray is now a market leader in the Australian \$70 million market. This product is supplied on prescriptions from Doctors by a pharmacy directly to the patient and competes directly with Pfizer's Viagra, Eli Lilly's Cialis and Bayer's Levitra. . The Australian ED market is approximately 1/20th of the US market in terms of market size.

Premature Ejaculation (PE)

According to a global study of sexual attitudes and behaviours¹, 14% of the male population suffers from PE compared with 10% who suffer from ED. This suggests that the market for PE treatment may be significantly larger than the US\$3.8 billion ED

¹ Sexual behaviour and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviours. Urology 2004 64: 991-997.

market. Treatment options are limited and there is no licensed competitive product that addresses this market need.

Female Sexual Dysfunction (FSD)

Female sexual dysfunction affects as many as four in every 10 women at some point in their lives. NxGen has developed a gel formulation to address FSD in the Australian market. While it is too early to project future sales of this product the initial uptake has been encouraging.

NxGen's Strong pipeline of future products

Naltrexone – Addiction Implants

NxGen has developed a time release naltrexone implant that is effective against alcoholism, nicotine, gambling and opiate addictions. Clinical trials will shortly commence for NxGen's alcohol, nicotine and opiate substance abuse products.

Chronic Dosage Injectable Implant

Future projects include implants for methamphetamine (ice) and cocaine addiction.

Local Topical Anaesthetic

A fast acting local anaesthetic for use in children and cosmetic application is about to begin Phase 1 Clinical Trials. NxGen has already established there is a large overseas market with distribution networks in Japan and Europe.

Innovative Erectile Dysfunction Product Development

Phase 1 development of a novel delivery platform for new ED formulation.